CD274 and neoplasm: Distinct molecular subtypes13–18 derived from rich genomic resources, including high tumor mutational burden (TMB) and high PDL1 protein expression, have also been associated with beneficial responses to checkpoint inhibitor therapies in NSCLC1,19–21.